pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.
Forward-Looking Statements
This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of Micromet's BiTE antibody MT110, which targets the epithelial cell adhesion molecule (EpCAM), currently in a phase 1 clinical trial for the treatment of patients with solid tumors, and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon fur
'/>"/>
SOURCE Micromet, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference2.
Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum3.
Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings4.
Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference5.
Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 20076.
Micromet, Inc. Elects Joseph P. Slattery to Board of Directors7.
Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 20078.
Micromet to Present at Two Upcoming Investor Conferences9.
Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 200810.
Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results11.
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results